Description
This listing combines cagrilintide and semaglutide as a co-formulated research pairing — the amylin/GLP-1 dual-hormone approach studied under the CagriSema program. Because amylin and GLP-1 act on separate receptor systems that both influence satiety, researchers use this combination to model additive or synergistic appetite-signalling effects that neither hormone produces alone.
Trial-stage data on cagrilintide+semaglutide co-administration has reported greater weight-related effect sizes than semaglutide monotherapy, which is why this pairing is increasingly requested for comparative dual-hormone research rather than single-agonist work.
After you place your order, a licensed physician will speak with you directly on a live call to review your health history and confirm a prescription is medically appropriate before anything ships. If your order isn’t approved, our team will contact you directly instead of shipping it. Reconstitute each component with bacteriostatic water per standard protocol and store refrigerated, protected from light.
